Cancer ColorectalFECCoNCT04592003
French Colorectal ESD Cohort in Experts Centers
An observational study of Cancer Colorectal and Polyps Colorectal, run by University Hospital, Limoges at 25 sites in France.
Trial summary
Initially developed in Japan for the treatment of endemic superficial gastric cancers, endoscopic submucosal dissection (ESD) allows resection of pre-neoplastic and neoplastic lesions of the digestive tract into a single fragment. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer Colorectal, Polyps Colorectal, Endoscopic Submucosal Resection
- What is being tested?
- Endoscopic submucosal dissection
- Type of treatment
- Surgery or procedure
- How many people
- 1,200 participants
- Where
- 25 sitesFrance
- Study dates
- 1 Jan 2020to 1 Jan 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All patients addressed for a colorectal ESD
Who may be able to join
- All patients addressed for a colorectal ESD
Who cannot join
- Opposition notified in the context of a non-opposition form after reading the information notice
Trial locations and contacts
25 sites in 1 country. Contact the study team or a site near you to ask about taking part.
25 sites in 1 country
France25 sites, 25 recruiting
- Recruiting
CHU d'Amiens
Amiens, 80054
Clara CY YZET, Dr, yzet.clara@chu-amiens.fr
- Recruiting
Clinique de l'Anjou
Angers, 49044
Edouard EC CHABRUN, Dr, echabrun@gmail.com
- Recruiting
CHU de Besançon
Besançon, 25000
Stéphane SK KOCH, Dr, stephkoch65@gmail.com
- Recruiting
CHU de Bordeaux
Bordeaux, 33400
Arthur AB BERGER, Dr, arthur.berger@chu-bordeaux.fr
- Recruiting
CHRU de Brest
Brest, 29200
Lucille LQ QUENERHVE, Dr, lucille.queneherve@gmail.com
- Recruiting
CHU de Dijon
Dijon, 21000
Thibault TD DEGAND, Dr, thibault.degand@chu-dijon.fr
- Recruiting
CHU de Limoges
Limoges, 87045
Jérémie JJ Jacques, Pr, 05 55 05 87 72, jérémie.jacques@chu-limoges.fr
- Recruiting
Hopital Edouard Herriot
Lyon, 69003
Mathieu MP PIOCHE, Pr, mathieu.pioche@chu-lyon.fr
- Recruiting
Hôpital Jean Mermoz
Lyon, 69008
Vincent VL LEPILLIEZ, Dr
Sarah SL LEBALNC, Dr, arahleblanc34@hotmail.com
- Recruiting
Hôpital Européen
Marseille, 13003
Maxime MP PALAZZO, Dr, palazzomaxime@gmail.com
- Recruiting
CHU de Montpellier
Montpellier, 34090
Antoine AB DEBOURDEAU, Dr, a-debourdeau@chu-montpellier.fr
- Recruiting
CHU de Nancy
Nancy, 54035
Jean-Baptiste JBC CHEVAUX, Dr, JB.CHEVAUX@chru-nancy.fr
- Recruiting
Clinique Jules Vernes
Nantes, 44000
Bertrand BB BRIEAU, Dr, bertrand.brieau@gmail.com
- Recruiting
CHU de Nantes
Nantes, 44093
Emmanuel EC CORON, Pr, Emmanuel.CORON@chu-nantes.fr
- Recruiting
CHU de Nice
Nice, 06200
Geoffroy VANBIERVLIET GW Geoffroy VANBIERVLIET, Pr, vanbiervliet.g@chu-nice.fr
- Recruiting
CHU de Nîmes
Nîmes, 30029
Ludovic LC CAILLO, Dr, ludovic.caillo@chu-nimes.fr
- Recruiting
Hôpital St Antoine
Paris, 75012
Xavier XD DRAY, Dr, xavier.dray@aphp.fr
- Recruiting
Hôpital Cochin - APHP
Paris, 75014
Stanislas SC CHAUSSADE, Pr, stanislas.chaussade@aphp.fr
- Recruiting
Hôpital St Joseph
Paris, 75014
Yann YLB LE-BALEUR, Dr, ylebaleur@hpsj.fr
- Recruiting
Hôpital Européen Georges Pompidou-APHP
Paris, 75015
Gabriel GR RAHMI, Pr, gabriel.rahmi@aphp.fr
- Recruiting
CHU de Rennes
Rennes, 35000
Timothee TW WALLENHORST, Dr, timothee.wallenhorst@chu-rennes.fr
- Recruiting
CHU de Rouen
Rouen, 76031
Chloé CM MELCHIOR, Pr, chloe.melchior@chu-rouen.fr
- Recruiting
Clinique Santé Atlantique
Saint-Herblain, 44800
Nicolas MUSQUER, Dr, drnicolasmusquer@outlook.fr
- Recruiting
CHU de Strasbourg
Strasbourg, 67000
Lucile LH HEROIN, Dr, lucileheroin@gmail.com
- Recruiting
CHU de Toulouse
Toulouse, 31400
Karl KB BARANGE, Dr, barange.k@chu-toulouse.fr
About this study
Initially developed in Japan for the treatment of endemic superficial gastric cancers, endoscopic submucosal dissection (ESD) allows resection of pre-neoplastic and neoplastic lesions of the digestive tract into a single fragment. It allows a perfect pathological analysis, and decreases the rate of recurrence of the adenoma to less than 2%. However, this procedure, which is technically more challenging, is also more risky (perforation rate at 4% vs. 1% for WF-EMR) and longer. Submucosal dissection is also more expensive in terms of equipment, but this difference can be offset by the cost of the high number of iterative colonoscopies required in patients who have had endoscopic resection by WF-EMR.
Scientific debate is agitating the Western world1,2 and Japanese experts do not perform WF-EMR anymore, whereas no comparative prospective study has compared these two procedures.
Read more
A lot of centers in France performed colorectal ESD even for benign lesions and nationwide data about safety and efficiency is required to confirm the place of ESD for treatment of large superficial colorectal lesions.
The aim of this French multicenter cohort is to analyze the results of colorectal submucosal dissection on a large scale.
Read the detailed description
Initially developed in Japan for the treatment of endemic superficial gastric cancers, endoscopic submucosal dissection (ESD) allows resection of pre-neoplastic and neoplastic lesions of the digestive tract into a single fragment. It allows a perfect pathological analysis, and decreases the rate of recurrence of the adenoma to less than 2%. However, this procedure, which is technically more challenging, is also more risky (perforation rate at 4% vs. 1% for WF-EMR) and longer. Submucosal dissection is also more expensive in terms of equipment, but this difference can be offset by the cost of the high number of iterative colonoscopies required in patients who have had endoscopic resection by WF-EMR.
Scientific debate is agitating the Western world1,2 and Japanese experts do not perform WF-EMR anymore, whereas no comparative prospective study has compared these two procedures.
A lot of centers in France performed colorectal ESD even for benign lesions and nationwide data about safety and efficiency is required to confirm the place of ESD for treatment of large superficial colorectal lesions.
The aim of this French multicenter cohort is to analyze the results of colorectal submucosal dissection on a large scale.
- Being tested
- Endoscopic submucosal dissection
- Keywords
- Cancer colorectal, Polyps colorectal, Endoscopic submucosal resection
- Medical subject headings
- Colonic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Endoscopic submucosal dissectionProcedure or surgery
Endoscopic submucosal dissection
| Study group | Role | What they receive |
|---|---|---|
| FECCo : French Esd Colorectal Cohort in Experts Centers | All patients over 18 years of age referred for submucosal dissection of a polyp or a colorectal LST in the French centers participating in the cohort. Receives: Procedure: Endoscopic submucosal dissection |
What is being measured
The primary outcome is the main question the study is designed to answer.
R0 Resection rate of submucosal dissection for superficial colorectal lesions
R0 Resection rate according to the definition of of the European Society of Gastrointestinal Endoscopy.
Measured: Month 1
Secondary outcomes (16)
Endoscopic recurrence rate during the first endoscopic follow-up
Recurrence during the first endoscopic follow-up will be defined by the presence of adenoma or adenocarcinoma at the resection scar, whether visible or not, and confirmed by systematic biopsies of the resection scar.
Measured: Month 6
Monobloc resection rate
Monobloc resection is defined as resection of the lesion in a single piece.
Measured: Day 1
Monobloc resection rate exclusively in ESD.
Monobloc resection exclusively by ESD is defined as resection of the lesion in a single piece using submucosal dissection only, without the use of a diathermic loop (hybrid technique).
Measured: Day 1
Curative resection rate
Curative resection is defined according to the recommendations of the European Society of Digestive Endoscopy as a monobloc R0 dissection without any negative anatomopathological criteria (well-differentiated lesion, no emboli, no budding > 1, submucosal infiltration < 1 mm).
Measured: Month 1
Optimal dissection rate
Optimal dissection is defined as exclusive R0 dissection without perforation, with a resection speed > 20 mm2/min.
Measured: Month 1
30-day complication rate
- Per-procedural perforation: breach of the colonic musculature with visualization of the peritoneal cavity.
- Post-procedural perforation (≤ 30 days): abdominal pain associated with fever or inflammatory syndrome and presence of extraluminal air on abdominal-pelvic CT scan, in the absence of per-procedural perforation.
- Per-procedural hemorrhage: considered a complication only if it leads to interruption of the procedure.
- Post-procedural hemorrhage: rectal bleeding or melena requiring hospitalization (or prolonged hospitalization) or endoscopic hemostasis.
Measured: Month 1
Curative endoscopic resection rate without surgical management at 36 months
Curative endoscopic resection without surgery is defined by the absence of adenoma or adenocarcinoma at the resection scar after 36 months of follow-up, regardless of the number of endoscopic treatments required.
Measured: Month 36
Number of metachronous colorectal lesions at 36 months
A metachronous lesion is defined as the presence of a new superficial colorectal lesion during one of the endoscopic checks, a lesion not visualized during one of the previous examinations.
Measured: Month 36
Surgery rate at 36 months
Any colorectal surgery will be taken into account, whether due to failure of the endoscopic procedure, recurrence, a complication of the procedure, or an anatomopathological reason.
Measured: Month 36
Recurrence rate at 36 months
Recurrence at 36 months will be defined by the presence of adenoma or adenocarcinoma at the resection scar, whether visible or not, and confirmed by systematic biopsies of the resection scar.
Measured: Month 36
Effectiveness of histological prediction of superficial colorectal lesions treated according to the technological tools used.
The histological prediction of resected lesions will be established using validated classifications (Paris, SANO, NICE, KUDO, JNET, CONECTT). It will be compared with the definitive histological results to assess their sensitivity, specificity, and diagnostic accuracy within the cohort.
Measured: Month 1
Impact of center volume on oncological outcomes, technical outcomes, and procedural complications.
Oncological, technical, and complication outcomes will be analyzed according to the annual volume of the centers (low volume = < 50 ESDs per year; intermediate volume = between 50 and 100 procedures per year; high volume = > 100 procedures per year).
Measured: Month 1
Compare oncological and technical outcomes and procedural complications based on colonic or rectal location.
Oncological, technical, and complication outcomes will be analyzed according to the colonic or rectal location of the lesion.
Measured: Month 1
Compare procedural outcomes based on the different traction strategies used
Oncological, technical, and complication outcomes will be analyzed according to the traction system used for the procedure, matching lesions according to difficulty criteria validated by the literature.
Measured: Month 1
Analyze the learning curve of new trainees at the time of implementation of the submucosal dissection curriculum of the French Society of Digestive Endoscopy.
The learning curve of trainees will be used to evaluate oncological, technical, and complication outcomes using the LC CUSUM method.
Measured: statitistic analysis
Creation of a difficulty score predicting the success of ESD (R0 resection without perforation)
A difficulty score predicting success (R0 without perforation) will be created by performing a multivariate analysis according to the TRIPOD GUIDELINES using a derivation cohort and validated on a derivation cohort.
Measured: Month 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Oct 2020
- Study start1 Jan 2020
- Primary completion1 Jan 2026 (estimated)
- Study completion1 Jan 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Cancer ColorectalStudies of the same condition, open and under way.
- More trials run by University Hospital, LimogesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 1,200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Limoges
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jérémie Jacques, Pr, Principal investigator, Service d'Hépato-Gastro-Entérologie et Nutrition du CHU de LIMOGES
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04592003
- Sponsor's protocol ID
- 87RI20-0021_FECCo
- Acronym
- FECCo
- Status last verified
- Aug 2025
- First submitted
- 8 Oct 2020
- Last updated
- 15 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Van der Voort V, Schaefer M, Wallenhorst T, Lepilliez V, Degand T, Le Baleur Y, Leclercq P, Berger A, Chabrun E, Brieau B, Barret M, Rahmi G, Legros R, Rivory J, Leblanc S, Vanbiervliet G, Alfarone L, Magne J, Zeevaert JB, Albouys J, Perrod G, Yzet C, Lepetit H, Belle A, Chaussade S, Rostain F, Dahan M, Lupu A, Chevaux JB, Pioche M, Jacques J; FECCo Group collaborators. Rectal versus colonic submucosal cancer rates and procedural outcomes in large non-pedunculated polyps: French ESD registry data. Gut. 2025 Oct 12:gutjnl-2024-332970. doi: 10.1136/gutjnl-2024-332970. Online ahead of print.
PubMed 41083216Yzet C, Wallenhorst T, Jacques J, Figueiredo Ferreira M, Rivory J, Rostain F, Masgnaux LJ, Grimaldi J, Legros R, Lafeuille P, Albouys J, Subtil F, Schaefer M, Pioche M. Traction-assisted endoscopic submucosal dissection for resection of ileocecal valve neoplasia: a French retrospective multicenter case series. Endoscopy. 2024 Oct;56(10):790-796. doi: 10.1055/a-2316-4910. Epub 2024 Apr 29.
PubMed 38684193Yzet C, Le Baleur Y, Albouys J, Jacques J, Doumbe-Mandengue P, Barret M, Abou Ali E, Schaefer M, Chevaux JB, Leblanc S, Lepillez V, Privat J, Degand T, Wallenhorst T, Rivory J, Chaput U, Berger A, Aziz K, Rahmi G, Coron E, Kull E, Caillo L, Vanbiervliet G, Koch S, Subtil F, Pioche M. Use of endoscopic submucosal dissection or full-thickness resection device to treat residual colorectal neoplasia after endoscopic resection: a multicenter historical cohort study. Endoscopy. 2023 Nov;55(11):1002-1009. doi: 10.1055/a-2116-9930. Epub 2023 Jul 27.
PubMed 37500072Patenotte A, Yzet C, Wallenhorst T, Subtil F, Leblanc S, Schaefer M, Walter T, Lambin T, Fenouil T, Lafeuille P, Chevaux JB, Legros R, Rostain F, Rivory J, Jacques J, Lepilliez V, Pioche M. Diagnostic endoscopic submucosal dissection for colorectal lesions with suspected deep invasion. Endoscopy. 2023 Feb;55(2):192-197. doi: 10.1055/a-1866-8080. Epub 2022 Jun 1.
PubMed 35649429
Study at a glance
From the registry record, last updated by the sponsor on 15 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- French Colorectal ESD Cohort in Experts Centers
- ClinicalTrials.gov ID
- NCT04592003
- Acronym / sponsor ID
- FECCo / 87RI20-0021_FECCo
- Keywords
- Cancer colorectal, Polyps colorectal, Endoscopic submucosal resection
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 1,200 participants (estimated)
- Lead sponsor
- University Hospital, LimogesUniversity, hospital or other
- Study start
- 1 Jan 2020 (actual)
- Primary completion
- 1 Jan 2026 (estimated)
- Study completion
- 1 Jan 2026 (estimated)
- First posted
- 19 Oct 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Initially developed in Japan for the treatment of endemic superficial gastric cancers, endoscopic submucosal dissection (ESD) allows resection of pre-neoplastic and neoplastic lesions of the digestive tract into a single fragment. It allows a perfect pathological analysis, and decreases the rate of recurrence of the adenoma to less than 2%. However, this procedure, which is technically more challenging, is also more risky (perforation rate at 4% vs. 1% for WF-EMR) and longer. Submucosal dissection is also more expensive in terms of equipment, but this difference can be offset by the cost of the high number of iterative colonoscopies required in patients who have had endoscopic resection by WF-EMR.
Scientific debate is agitating the Western world1,2 and Japanese experts do not perform WF-EMR anymore, whereas no comparative prospective study has compared these two procedures.
A lot of centers in France performed colorectal ESD even for benign lesions and nationwide data about safety and efficiency is required to confirm the place of ESD for treatment of large superficial colorectal lesions.
The aim of this French multicenter cohort is to analyze the results of colorectal submucosal dissection on a large scale.
Detailed description
Initially developed in Japan for the treatment of endemic superficial gastric cancers, endoscopic submucosal dissection (ESD) allows resection of pre-neoplastic and neoplastic lesions of the digestive tract into a single fragment. It allows a perfect pathological analysis, and decreases the rate of recurrence of the adenoma to less than 2%. However, this procedure, which is technically more challenging, is also more risky (perforation rate at 4% vs. 1% for WF-EMR) and longer. Submucosal dissection is also more expensive in terms of equipment, but this difference can be offset by the cost of the high number of iterative colonoscopies required in patients who have had endoscopic resection by WF-EMR.
Scientific debate is agitating the Western world1,2 and Japanese experts do not perform WF-EMR anymore, whereas no comparative prospective study has compared these two procedures.
A lot of centers in France performed colorectal ESD even for benign lesions and nationwide data about safety and efficiency is required to confirm the place of ESD for treatment of large superficial colorectal lesions.
The aim of this French multicenter cohort is to analyze the results of colorectal submucosal dissection on a large scale.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| FECCo : French Esd Colorectal Cohort in Experts Centers | – | Procedure: Endoscopic submucosal dissectionAll patients over 18 years of age referred for submucosal dissection of a polyp or a colorectal LST in the French centers participating in the cohort. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All patients addressed for a colorectal ESD
Key inclusion criteria (1 listed)
- All patients addressed for a colorectal ESD
Key exclusion criteria (1 listed)
- Opposition notified in the context of a non-opposition form after reading the information notice
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Endoscopic submucosal dissectionEndoscopic submucosal dissection | Procedure or surgery | FECCo : French Esd Colorectal Cohort in Experts Centers |
Primary outcome
R0 Resection rate of submucosal dissection for superficial colorectal lesions
Time frame: Month 1
R0 Resection rate according to the definition of of the European Society of Gastrointestinal Endoscopy.
16 secondary outcomes
Endoscopic recurrence rate during the first endoscopic follow-up
Time frame: Month 6
Monobloc resection rate
Time frame: Day 1
Monobloc resection rate exclusively in ESD.
Time frame: Day 1
Curative resection rate
Time frame: Month 1
Optimal dissection rate
Time frame: Month 1
30-day complication rate
Time frame: Month 1
Curative endoscopic resection rate without surgical management at 36 months
Time frame: Month 36
Number of metachronous colorectal lesions at 36 months
Time frame: Month 36
Surgery rate at 36 months
Time frame: Month 36
Recurrence rate at 36 months
Time frame: Month 36
Effectiveness of histological prediction of superficial colorectal lesions treated according to the technological tools used.
Time frame: Month 1
Impact of center volume on oncological outcomes, technical outcomes, and procedural complications.
Time frame: Month 1
Compare oncological and technical outcomes and procedural complications based on colonic or rectal location.
Time frame: Month 1
Compare procedural outcomes based on the different traction strategies used
Time frame: Month 1
Analyze the learning curve of new trainees at the time of implementation of the submucosal dissection curriculum of the French Society of Digestive Endoscopy.
Time frame: statitistic analysis
Creation of a difficulty score predicting the success of ESD (R0 resection without perforation)
Time frame: Month 1
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Sep 2025.
- Derived from this study: PubMed 41083216Van der Voort V, Schaefer M, Wallenhorst T, Lepilliez V, Degand T, Le Baleur Y, Leclercq P, Berger A, Chabrun E, Brieau B, Barret M, Rahmi G, Legros R, Rivory J, Leblanc S, Vanbiervliet G, Alfarone L, Magne J, Zeevaert JB, Albouys J, Perrod G, Yzet C, Lepetit H, Belle A, Chaussade S, Rostain F, Dahan M, Lupu A, Chevaux JB, Pioche M, Jacques J; FECCo Group collaborators. Rectal versus colonic submucosal cancer rates and procedural outcomes in large non-pedunculated polyps: French ESD registry data. Gut. 2025 Oct 12:gutjnl-2024-332970. doi: 10.1136/gutjnl-2024-332970. Online ahead of print.
- Derived from this study: PubMed 38684193Yzet C, Wallenhorst T, Jacques J, Figueiredo Ferreira M, Rivory J, Rostain F, Masgnaux LJ, Grimaldi J, Legros R, Lafeuille P, Albouys J, Subtil F, Schaefer M, Pioche M. Traction-assisted endoscopic submucosal dissection for resection of ileocecal valve neoplasia: a French retrospective multicenter case series. Endoscopy. 2024 Oct;56(10):790-796. doi: 10.1055/a-2316-4910. Epub 2024 Apr 29.
- Derived from this study: PubMed 37500072Yzet C, Le Baleur Y, Albouys J, Jacques J, Doumbe-Mandengue P, Barret M, Abou Ali E, Schaefer M, Chevaux JB, Leblanc S, Lepillez V, Privat J, Degand T, Wallenhorst T, Rivory J, Chaput U, Berger A, Aziz K, Rahmi G, Coron E, Kull E, Caillo L, Vanbiervliet G, Koch S, Subtil F, Pioche M. Use of endoscopic submucosal dissection or full-thickness resection device to treat residual colorectal neoplasia after endoscopic resection: a multicenter historical cohort study. Endoscopy. 2023 Nov;55(11):1002-1009. doi: 10.1055/a-2116-9930. Epub 2023 Jul 27.
- Derived from this study: PubMed 35649429Patenotte A, Yzet C, Wallenhorst T, Subtil F, Leblanc S, Schaefer M, Walter T, Lambin T, Fenouil T, Lafeuille P, Chevaux JB, Legros R, Rostain F, Rivory J, Jacques J, Lepilliez V, Pioche M. Diagnostic endoscopic submucosal dissection for colorectal lesions with suspected deep invasion. Endoscopy. 2023 Feb;55(2):192-197. doi: 10.1055/a-1866-8080. Epub 2022 Jun 1.
Related trials for Cancer Colorectal
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingObservational study
Pre- and On-treatment Multi-omics Profiling of Locally Advanced Rectal Cancer
Rectal Neoplasms
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 2
Tislelizumab in People With Colorectal Cancer
Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jérémie Jacques, Pr principal investigator
Service d'Hépato-Gastro-Entérologie et Nutrition du CHU de LIMOGES
25 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer Colorectal and Polyps Colorectal, run by University Hospital, Limoges at 25 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 25 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jérémie Jacques, Pr (05 55 05 87 72, jeremie.jacques@chu-limoges.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
R0 Resection rate of submucosal dissection for superficial colorectal lesions (time frame: Month 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04592003, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Sep 2025.